Moderna Initiates Rolling Submission To Health Canada For Updated Covid-19 Vaccine
Portfolio Pulse from Happy Mohamed
Moderna has initiated a rolling New Drug Submission to Health Canada for its updated COVID-19 vaccine, SPIKEVAX® XBB.1.5, targeting the omicron subvariant XBB.1.5 of SARS-CoV-2. This follows Moderna's submission to the U.S. FDA for authorization. The company is prepared to deliver the updated vaccines in time for the fall 2023 vaccination season.
June 29, 2023 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's initiation of a new drug submission for its updated COVID-19 vaccine to Health Canada could potentially boost its stock as it indicates progress and potential market expansion.
The news of Moderna's submission to Health Canada for its updated COVID-19 vaccine is directly relevant to the company and its stock. If approved, this could lead to increased sales and revenue for Moderna, which would likely have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100